{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T19:13:45Z","timestamp":1771701225097,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:00:00Z","timestamp":1716076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.canlet.2024.216970","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T03:48:56Z","timestamp":1716004136000},"page":"216970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia"],"prefix":"10.1016","volume":"593","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3946-6305","authenticated-orcid":false,"given":"Dan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daolin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-1209","authenticated-orcid":false,"given":"Minghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216970_bib1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.216970_bib2","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.216970_bib3","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216970_bib4","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2019001728","article-title":"Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period","volume":"134","author":"Juliusson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216970_bib5","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216970_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","article-title":"Venetoclax combined with azacitidine and homoharringtonine in relapsed\/refractory AML: a multicenter, phase 2 trial","volume":"16","author":"Jin","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-023-01476-8","article-title":"A phase 1\/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents","volume":"16","author":"Short","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216970_bib9","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib10","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3324\/haematol.2023.282681","article-title":"Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia","volume":"108","author":"Gutman","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2024.216970_bib11","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3324\/haematol.2022.281563","article-title":"Results from a phase I\/II trial of epratuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"108","author":"Pabst","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2024.216970_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-023-00871-1","article-title":"A Phase I study of Miladies (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: clinical safety, efficacy, and correlative analysis","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2024.216970_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib15","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-20-2950","article-title":"Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial","volume":"27","author":"Li","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216970_bib16","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.21.02091","article-title":"Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial","volume":"40","author":"Xu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib17","doi-asserted-by":"crossref","first-page":"e1693","DOI":"10.1002\/onco.13857","article-title":"Anlotinib monotherapy for refractory metastatic colorectal cancer: a double-blinded, placebo-controlled, randomized phase III trial (ALTER0703)","volume":"26","author":"Chi","year":"2021","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib18","article-title":"Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: a multi-center, single-arm, phase 1b trial","volume":"3","author":"Lan","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.canlet.2024.216970_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.32548","article-title":"Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis","volume":"77","author":"Zhou","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2024.216970_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110837","article-title":"Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo","volume":"110","author":"Zhang","year":"2023","journal-title":"Cell. Signal."},{"key":"10.1016\/j.canlet.2024.216970_bib21","first-page":"1494","article-title":"Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth by inhibiting SETD1A\/AKT-mediated DNA damage response","volume":"13","author":"Chen","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.canlet.2024.216970_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ph15111313","article-title":"Preclinical evaluation of the multiple tyrosine kinases inhibitor anlotinib in leukemia stem cells","volume":"15","author":"Jiang","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.canlet.2024.216970_bib23","doi-asserted-by":"crossref","first-page":"774","DOI":"10.20892\/j.issn.2095-3941.2022.0006","article-title":"Anti-tumor pharmacology of natural products targeting mitosis","volume":"19","author":"Huang","year":"2022","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.canlet.2024.216970_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100742","article-title":"Taxanes in cancer treatment: activity, chemoresistance and its overcoming","volume":"54","author":"Mosca","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2024.216970_bib25","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.canlet.2024.216970_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266478","article-title":"VCP inhibition induces an unfolded protein response and apoptosis in human acute myeloid leukemia cells","volume":"17","author":"Szcz\u0119\u015bniak","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216970_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg1168","article-title":"Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor","volume":"13","author":"Roux","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216970_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41419-020-02762-w","article-title":"Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway","volume":"11","author":"Shi","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.216970_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216970_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib31","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/itd+ acute myeloid leukemia: a report from the children's oncology group protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-022-01309-0","article-title":"A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase","volume":"15","author":"Garc\u00eda-Guti\u00e9rrez","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1083\/jcb.201708105","article-title":"ENSA and ARPP19 differentially control cell cycle progression and development","volume":"218","author":"Hached","year":"2019","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216970_bib34","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1126\/science.1195689","article-title":"Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis","volume":"330","author":"Mochida","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216970_bib35","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1126\/science.1197048","article-title":"The substrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A","volume":"330","author":"Gharbi-Ayachi","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216970_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41388-021-02068-x","article-title":"PP2A-B55: substrates and regulators in the control of cellular functions","volume":"41","author":"Amin","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216970_bib37","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.20892\/j.issn.2095-3941.2022.0330","article-title":"Targeting PP2A for cancer therapeutic modulation","volume":"19","author":"Ronk","year":"2022","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.canlet.2024.216970_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2024.216970_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-019-0821-7","article-title":"Preclinical efficacy for a novel tyrosine kinase inhibitor, Marquee 531 against acute myeloid leukemia","volume":"13","author":"Elgamal","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib40","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/s41375-020-0764-6","article-title":"Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia","volume":"34","author":"Eide","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216970_bib41","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216970_bib43","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216970_bib44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.canlet.2024.216970_bib45","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4149\/neo_2022_211012N1441","article-title":"Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING\/IFN-\u03b2 pathway","volume":"69","author":"Yuan","year":"2022","journal-title":"Neoplasma"},{"key":"10.1016\/j.canlet.2024.216970_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106668","article-title":"Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET\/MYC\/AXL axis","volume":"188","author":"Lei","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2024.216970_bib47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","article-title":"Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma","volume":"28","author":"Su","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216970_bib48","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2022016466","article-title":"Activation of the PP2A-B56\u03b1 heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation","volume":"141","author":"Peris","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216970_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13062-021-00313-7","article-title":"A link between mitotic defects and mitotic catastrophe: detection and cell fate","volume":"16","author":"Sazonova","year":"2021","journal-title":"Biol. Direct"},{"key":"10.1016\/j.canlet.2024.216970_bib50","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.kint.2022.04.027","article-title":"Myeloid-derived growth factor deficiency exacerbates mitotic catastrophe of podocytes in glomerular disease","volume":"102","author":"Zhan","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.canlet.2024.216970_bib51","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s11010-022-04470-9","article-title":"SIRT1 regulates mitotic catastrophe via autophagy and BubR1 signaling","volume":"477","author":"Zhao","year":"2022","journal-title":"Mol. Cell. Biochem."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T18:52:58Z","timestamp":1720291978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524003641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":51,"alternative-id":["S0304383524003641"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216970","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216970"}}